Ovarian Clear Cell Carcinoma Sub-Typing by ARID1A Expression
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: Loss of AT-rich DNA-interacting domain 1A (ARID1A) has been identified as a driving mutation of ovarian clear cell carcinoma (O-CCC), a triple-negative ovarian cancer that is intermediary between serous and endometrioid subtypes, in regards to molecular and clinical behaviors. However, about half of O-CCCs still express BAF250a, the protein encoded by ARID1A. Herein,we aimed to identify signatures of ARID1A-positive O-CCC in comparison with its ARID1A-negative counterpart. Materials and Methods: Seventy cases of O-CCC were included in this study. Histologic grades and patterns of primary tumor, molecular marker immunohistochemistry profiles, and clinical outcomes were analyzed. Results: Forty-eight (69%) O-CCCs did not express BAF250a, which were designated as “ARID1A-negative.” The other 22 (31%) O-CCCs were designated as “ARID1A-positive.” ARID1A-positive tumors were more likely to be histologically of high grades (41% vs. 10%, p=0.003), ERβ-positive (45% vs. 17%, p=0.011), and less likely to be HNF1β-positive (77% vs. 96%, p=0.016) and E-cadherin-positive (59% vs. 83%, p=0.028) than ARID1A-negative tumors. Patient age, parity, tumor stage were not significantly different in between the two groups. Cancer-specific survival was not significantly different either. Conclusion: We classified O-CCCs according to ARID1A expression status. ARID1A-positive O-CCCs exhibited distinct immunohistochemicalfeatures from ARID1A-negative tumors, suggesting a different underlying molecular event during carcinogenesis.
Abstract
Purpose: Loss of AT-rich DNA-interacting domain 1A (ARID1A) has been identified as a driving mutation of ovarian clear cell carcinoma (O-CCC), a triple-negative ovarian cancer that is intermediary between serous and endometrioid subtypes, in regards to molecular and clinical behaviors. However, about half of O-CCCs still express BAF250a, the protein encoded by ARID1A. Herein,we aimed to identify signatures of ARID1A-positive O-CCC in comparison with its ARID1A-negative counterpart. Materials and Methods: Seventy cases of O-CCC were included in this study. Histologic grades and patterns of primary tumor, molecular marker immunohistochemistry profiles, and clinical outcomes were analyzed. Results: Forty-eight (69%) O-CCCs did not express BAF250a, which were designated as “ARID1A-negative.” The other 22 (31%) O-CCCs were designated as “ARID1A-positive.” ARID1A-positive tumors were more likely to be histologically of high grades (41% vs. 10%, p=0.003), ERβ-positive (45% vs. 17%, p=0.011), and less likely to be HNF1β-positive (77% vs. 96%, p=0.016) and E-cadherin-positive (59% vs. 83%, p=0.028) than ARID1A-negative tumors. Patient age, parity, tumor stage were not significantly different in between the two groups. Cancer-specific survival was not significantly different either. Conclusion: We classified O-CCCs according to ARID1A expression status. ARID1A-positive O-CCCs exhibited distinct immunohistochemicalfeatures from ARID1A-negative tumors, suggesting a different underlying molecular event during carcinogenesis.
참고문헌 (35)
- Ahmed Q, "Gynecologic cancers: molecular updates", Clin Lab Med, 33, pp.911~925 (2013)
- Jones S, "Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma", Science, 330, pp.228~231 (2010)
- Wiegand KC, "ARID1A mutations in endometriosis-associated ovarian carcinomas", N Engl J Med, 363, pp.1532~1543 (2010)
- Yamamoto S, "Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations", Mod Pathol, 25, pp.615~624 (2012)
- Chene G, "The ARID1A pathway in ovarian clear cell and endometrioid carcinoma, contiguous endometriosis, and benign endometriosis", Int J Gynaecol Obstet, 130, pp.27~30 (2015)
- Reisman D, "The SWI", SNF complex and cancer, 2009, pp.28, 1653~1668
- Nagl NG Jr, "The c-myc gene is a direct target of mammalian SWI", SNF-related complexes during differentiation-associated cell cycle arrest, 2006, pp.66, 1289~1293
- Samartzis EP, "ARID1A mutations and PI3K", AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas, 2013, pp.14, 18824~18849
- Tanase Y, "Modulation of estrogenic action in clear cell carcinoma of the ovary (review)", Exp Ther Med, 3, pp.18~24 (2012)
- LaGrenade A, "Ovarian tumors associated with atypical endometriosis", Hum Pathol, 19, pp.1080~1084 (1988)
- Prefumo F, "Epithelial abnormalities in cystic ovarian endometriosis", Gynecol Oncol, 84, pp.280~284 (2002)
- Inoue H, "Largest subunits of the human SWI", SNF chromatin-remodeling complex promote transcriptional activation by steroid hormone receptors, 2002, pp.277, 41674~41685
- Lazennec G, "Estrogen receptor beta, a possible tumor suppressor involved in ovarian carcinogenesis", Cancer Lett, 231, pp.151~157 (2006)
- Banine F, "SWI", SNF chromatin-remodeling factors induce changes in DNA methylation to promote transcriptional activation, 2005, pp.65, 3542~3547
- Tsuchiya A, "Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma", Am J Pathol, 163, pp.2503~2512 (2003)
- Tomassetti A, "Variant HNF1 modulates epithelial plasticity of normal and transformed ovary cells", Neoplasia, 10, pp.1481~1492 (2008)
- Ye S, "Clinicopathologic significance of HNF-1β, AIRD1A, and PIK3CA expression in ovarian clear cell carcinoma: a tissue microarray study of 130 cases", Medicine (Baltimore), 95, pp.e3003~ (2016)
- Okamoto A, "Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary", Int J Gynecol Cancer, 24(9 Suppl 3), pp.S20~S25 (2014)
- Lee YY, "Prognosis of ovarian clear cell carcinoma compared to other histological subtypes:a meta-analysis", Gynecol Oncol, 122, pp.541~547 (2011)
- Itamochi H, "Loss of ARID1A expression is associated with poor prognosis in patients with stage I", II clear cell carcinoma of the ovary, 2015, pp.20, 967~973
- Zeppernick F, "The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer", Arch Gynecol Obstet, 290, pp.839~842 (2014)
- Xiao W, "Loss of ARID1A", BAF250a expression in ovarian endometriosis and clear cell carcinoma, 2012, pp.5, 642~650
- Ayhan A, "Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma", Int J Gynecol Cancer, 22, pp.1310~1315 (2012)
- Lin K, "Increased steroid receptor RNA activator protein (SRAP) accompanied by decreased estrogen receptor-beta (ER-β) levels during the malignant transformation of endometriosis associated ovarian clear cell carcinoma", Acta Histochem, 116, pp.878~882 (2014)
- Yan HB, "Reduced expression of the chromatin remodeling gene ARID1A enhances gastric cancer cell migration and invasion via downregulation of E-cadherin transcription", Carcinogenesis, 35, pp.867~876 (2014)
- Gounaris I, "Molecular pathogenesis of ovarian clear cell carcinoma", Future Oncol, 11, pp.1389~1405 (2015)
- Faleiro-Rodrigues C, "Prognostic value of E-cadherin immunoexpression in patients with primary ovarian carcinomas", Ann Oncol, 15, pp.1535~1542 (2004)
- Rahman M, "Clinicopathologic analysis of loss of AT-rich interactive domain 1A expression in endometrial cancer", Hum Pathol, 44, pp.103~109 (2013)
- Ryu SY, "Prognostic significance of histological grade in clear-cell carcinoma of the ovary:a retrospective study of Korean Gynecologic Oncology Group", Ann Oncol, 20, pp.1032~1036 (2009)
- Earp MA, "DNA methylation changes in epithelial ovarian cancer histotypes", Genomics, 106, pp.311~321 (2015)
- Yamaguchi K, "Epigenetic determinants of ovarian clear cell carcinoma biology", Int J Cancer, 135, pp.585~597 (2014)
- Shen H, "Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer", Nat Commun, 4, pp.1628~ (2013)
- 성혜윤, "Overexpression of Mucin 13 due to Promoter Methylation Promotes Aggressive Behavior in Ovarian Cancer Cells", Yonsei Medical Journal, 55(5), pp.1206~1213 (2014), 연세대학교의과대학[DOI]
- 안정혁, "DNA Hypomethylation-Mediated Overexpression of Carbonic Anhydrase 9 Induces an Aggressive Phenotype in Ovarian Cancer Cells", Yonsei Medical Journal, 55(6), pp.1656~1663 (2014), 연세대학교의과대학[DOI]
- Yamamoto S, "Validation of the histologic grading for ovarian clear cell adenocarcinoma: a retrospective multi-institutional study by the Japan Clear Cell Carcinoma Study Group", Int J Gynecol Pathol, 30, pp.129~138 (2011)